Aytu Biopharma Inc (AYTU)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 06/30
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -15,844 | -11,227 | -8,340 | -8,120 | -17,051 |
| Depreciation Amortization | 7,322 | 5,630 | 3,936 | 1,991 | 9,374 |
| Accounts receivable | 5,201 | -531 | -1,566 | -1,684 | -7,153 |
| Accounts payable and accrued liabilities | -2,076 | -2,210 | -3,062 | 946 | 2,384 |
| Other Working Capital | -4,660 | -4,618 | -5,035 | -1,351 | -5,799 |
| Other Operating Activity | 8,669 | 12,356 | 13,721 | 8,007 | 13,116 |
| Operating Cash Flow | $-1,388 | $-600 | $-346 | $-211 | $-5,129 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -329 | N/A | N/A | N/A | N/A |
| Other Investing Activity | 0 | -295 | -250 | -76 | -117 |
| Investing Cash Flow | $-329 | $-295 | $-250 | $-76 | $-117 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 832 | 18 | -537 | -348 | -2,250 |
| Debt Issued | 13,000 | N/A | N/A | N/A | N/A |
| Debt Repayment | -18,288 | -2,274 | -2,249 | -2,226 | -4,362 |
| Common Stock Issued | 3,467 | 86 | 86 | N/A | 15,575 |
| Other Financing Activity | -273 | -160 | -160 | -160 | -92 |
| Financing Cash Flow | $-1,262 | $-2,330 | $-2,860 | $-2,734 | $8,871 |
| Beginning Cash Position | 22,985 | 22,985 | 22,985 | 22,985 | 19,360 |
| End Cash Position | 20,006 | 19,760 | 19,529 | 19,964 | 22,985 |
| Net Cash Flow | $-2,979 | $-3,225 | $-3,456 | $-3,021 | $3,625 |
| Free Cash Flow | |||||
| Operating Cash Flow | -1,388 | -600 | -346 | -211 | -5,129 |
| Capital Expenditure | -329 | N/A | N/A | N/A | N/A |
| Free Cash Flow | -1,717 | -600 | -346 | -211 | -5,129 |